Exelixis' future depends on trial outcomes and patent risks. Find out why EXEL stock is a "Sell" despite cabozantinib's ...

RBC Capital raised the firm’s price target on Exelixis (EXEL) to $40 from $38 and keeps an Outperform rating on the shares. The firm notes ...

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...

In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Exelixis (EXEL – Research Report). The ...

In this article, we are going to take a look at where Exelixis, Inc. (NASDAQ:EXEL) stands against other best immunology stocks to buy now. The Growing Market for Immune System Treatments ...

Exelixis (NASDAQ:EXEL – Get Free Report) was downgraded by equities researchers at Wells Fargo & Company from an “overweight” rating to an “equal weight” rating in a research report issued to clients ...

Research analysts at Zacks Research dropped their Q1 2025 EPS estimates for Exelixis in a research report issued on Monday, March 3rd. Zacks Research analyst E. Bagri now forecasts that the ...

Exelixis is known for developing cancer therapies, with cabozantinib being central to its commercial offerings. This drug, marketed as CABOMETYX and COMETRIQ, remains a critical component of ...

On Tuesday, 11 March 2025, Exelixis (NASDAQ: EXEL) presented at the Barclays 27th Annual Global Healthcare Conference, offering insights into its strategic pipeline progress. The company ...

Renaissance Technologies' 13F reveals shifts in a $67.6B portfolio with notable changes in Palantir, Novo Nordisk, and NVIDIA ...